Codexis, Inc. (NASDAQ:CDXS) Receives $22.30 Average PT from Brokerages
Codexis, Inc. (NASDAQ:CDXS) has earned a consensus recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $22.30.
Several equities analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Garrett Motion from a “sell” rating to a “hold” rating in a report on Friday, May 10th. ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Finally, BidaskClub cut shares of Xilinx from a “buy” rating to a “hold” rating in a research note on Saturday, June 15th.
In other Codexis news, SVP James Lalonde sold 19,999 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $18.65, for a total transaction of $372,981.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.70% of the stock is owned by company insiders.
NASDAQ:CDXS traded down $0.31 during mid-day trading on Monday, hitting $18.53. 210,053 shares of the company’s stock traded hands, compared to its average volume of 395,812. The company has a current ratio of 3.42, a quick ratio of 3.38 and a debt-to-equity ratio of 0.51. The business has a 50 day simple moving average of $18.32. Codexis has a 1 year low of $12.85 and a 1 year high of $23.05. The stock has a market capitalization of $1.03 billion, a P/E ratio of -88.24 and a beta of -0.17.
Codexis (NASDAQ:CDXS) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.09). Codexis had a negative net margin of 18.22% and a negative return on equity of 21.08%. The firm had revenue of $15.58 million during the quarter, compared to the consensus estimate of $14.83 million. Research analysts anticipate that Codexis will post -0.23 earnings per share for the current year.
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Recommended Story: Hedge Funds Explained
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.